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Abstract
Polygenic type 2 diabetes in mouse models is associated with obesity and results from a combination of adipogenic and
diabetogenic alleles. Here we report the identification of a candidate gene for the diabetogenic effect of a QTL (Nidd/SJL,
Nidd1) contributed by the SJL, NON, and NZB strains in outcross populations with New Zealand Obese (NZO) mice. A critical
interval of distal chromosome 4 (2.1 Mbp) conferring the diabetic phenotype was identified by interval-specific congenic
introgression of SJL into diabetes-resistant C57BL/6J, and subsequent reporter cross with NZO. Analysis of the 10 genes in
the critical interval by sequencing, qRT–PCR, and RACE–PCR revealed a striking allelic variance of Zfp69 encoding zinc finger
domain transcription factor 69. In NZO and C57BL/6J, a retrotransposon (IAPLTR1a) in intron 3 disrupted the gene by
formation of a truncated mRNA that lacked the coding sequence for the KRAB (Kru ¨ppel-associated box) and Znf-C2H2
domains of Zfp69, whereas the diabetogenic SJL, NON, and NZB alleles generated a normal mRNA. When combined with the
B6.V-Lep
ob background, the diabetogenic Zfp69
SJL allele produced hyperglycaemia, reduced gonadal fat, and increased
plasma and liver triglycerides. mRNA levels of the human orthologue of Zfp69, ZNF642, were significantly increased in
adipose tissue from patients with type 2 diabetes. We conclude that Zfp69 is the most likely candidate for the diabetogenic
effect of Nidd/SJL, and that retrotransposon IAPLTR1a contributes substantially to the genetic heterogeneity of mouse
strains. Expression of the transcription factor in adipose tissue may play a role in the pathogenesis of type 2 diabetes.
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Introduction
Type 2 diabetes results from the combination of insulin
resistance and inadequate insulin secretion, the former being
associated with obesity [1]. The risk of developing type 2 diabetes
is to approximately 50% inherited [2]. Recently, numerous
associations between single nucleotide polymorphisms and the
diabetes risk in humans have been identified and confirmed [3–7].
However, little is known as to the functional consequences of these
SNPs at the molecular, cellular, and physiological level.
Obese mouse strains carrying the Lep
ob (ob) or the Lep
db (db)
mutation have proven to be valuable models for the study of the
pathophysiology and genetics of type 2 diabetes [8]. In these
strains, the adipogenic mutation is necessary, but not sufficient for
the development of severe hyperglycaemia and diabetes [9]. Thus,
the diabetic phenotype appeared to be conferred by the
background strain, and it was assumed that lean mice may carry
diabetogenic and/or diabetes-protecting alleles. Furthermore,
quantitative trait loci for obesity and hyperglycaemia were
separated in outcross experiments of New Zealand Obese (NZO)
mice and lean strains, proving the concept that diabetes is the
result of a combination of adipogenic and diabetogenic alleles [10–
13]. Subsequently, two genes that confer diabetes susceptibility of
obese strains have been identified. Sorcs1 is a gene involved in
microvasculature function, and contributes to diabetes in
BTBR.V(B6)-Lep
ob mice [14]. A variant of Lisch-like was shown
to be responsible in part for the diabetogenic effect of the DBA
background in mice carrying the adipogenic db mutation [15].
Lisch-like has been suggested to be involved in the development of
insulin-producing cells. Thus, positional cloning of mouse diabetes
genes may provide major insights into the pathogenesis of obesity-
associated diabetes.
We have previously identified a QTL (Nidd/SJL) on distal
chromosome 4 that aggravated and accelerated diabetes in an
outcross population of NZO with the lean SJL strain [11,12]. This
QTL exhibited high LOD scores for the trait blood glucose, and
reproducibly doubled the prevalence of diabetes in a NZOxSJL
backcross population [12]. In addition, it markedly enhanced the
effect of a second diabetes and obesity-modifying gene [16]. The
chromosomal position of Nidd/SJL is similar to that of a previously
PLoS Genetics | www.plosgenetics.org 1 July 2009 | Volume 5 | Issue 7 | e1000541described diabetogenic QTL (Nidd1, Figure 1) which has been
identified in an outcross of NZO with NON [10]. Interestingly, the
human syntenic region of Nidd1 and Nidd/SJL (human chromo-
some 1) comprises a QTL for reduced insulin secretion that was
identified in the Pima Indian population [17]. Furthermore, in a
recent metaanalysis of diabetogenic mouse QTL, distal chromo-
some 4 was among the 7 consensus regions with the highest
combined LOD scores [18]. Thus, Nidd/SJL appeared to be a
prime target for positional cloning of a novel mouse diabetes gene.
Results
Identification and fine-mapping of a critical diabetogenic
interval of Nidd/SJL
Figure 1A illustrates the position of the Nidd/SJL locus on distal
chromosome 4 [11,12] and its proximity to the previously
described Nidd1 [10]. For further analysis of the QTL, we
introgressed a segment of SJL chromosome 4 defined by the
markers D4Mit175 and D4Mit233 (Figure 1A) into the C57BL/6J
(B6) background. These mice (B6.SJL-Nidd/SJL) were lean and
exhibited no alteration in glucose homeostasis (data not shown).
Thus, B6.SJL-Nidd/SJL mice were then mated with NZO in order
to introduce obesity, and the resulting F1 was intercrossed or
backcrossed on NZO. Characterization of the N2 progeny
indicated that Nidd/SJL carriers exhibited early onsetting hyper-
glycaemia with blood glucose levels approximately 150 mg/dl
higher than in carriers of the NZO allele (Figure 1B), and stopped
gaining weight in week 10–12 (Figure 1C). Similar results were
obtained in the F2 intercross which showed an additive effect of
Nidd/SJL (Figure S1). It should be noted that carriers of the NZO
allele of Nidd/SJL also became hyperglycaemic, although to a
much lesser degree than carriers of the SJL allele (Figure 1B),
presumably due to other diabetogenic alleles from NZO
chromosomes 1 and 15 [10,11; Vogel et al., unpublished]. These
mice, however, continued to gain weight (Figure 1C), indicating
that the weight development could be used as an additional
criterion to determine the presence or absence of the causal gene
in Nidd/SJL.
For restriction of the critical segment of Nidd/SJL, interval-
specific congenic B6.SJL-Nidd/SJL mice carrying different seg-
ments of the QTL (Figure 2A) were mated with NZO and
backcrossed. Characterization of the N2 progeny with regard to
their blood glucose levels and development of body weight
indicated that segments I, II, and III were diabetogenic (Figure 2B).
Segment IV, in contrast, which serendipitously originated from
segment III in the final backcross to B6, failed to produce the
severe hyperglycaemia and growth arrest. Thus, the critical
interval of chromosome 4 comprising the diabetogenic allele was
defined by the markers D4Mit76 and D4Mit12 (Figure 2A). For
further fine mapping we used additional SNPs from the public
databases (Figure S2), thereby reducing the critical interval defined
by the genotypes of segments III and IV to 2.1 Mbp (Figure 3A
and Figure S2). The interval was flanked by Nfyc and Ppt1, and
contained 10 confirmed genes. The human syntenic region
contains two additional genes (Figure 3B; ZNF684 and ZNF643),
presumably duplications of ZNF642. Data base searches indicated
that these genes are not present in the mouse genome; their closest
mouse orthologue is Zfp69.
Analysis of the critical region by sequencing and mRNA
profiling
Sequencing of all 10 genes in the critical interval (Figure 3A)
identified non-synonymous substitutions in Zfp69 (T57I, A79V),
Smap2 (T257I), and Col9A2 (T298I, A482I, R610H). Zfp69
encodes a transcription factor; the amino acid exchanges are
located outside of its functional domains (zinc finger binding
domain, KRAB domain). Smap2 (stromal membrane-associated
protein 2; alias Smap1l) encodes an ARF-GTPase activating
protein which regulates protein trafficking from endosomes to
the Golgi [19,20]; its crystal structure has been determined [21].
In the SJL sequence, threonine 257 is exchanged for isoleucine;
the human orthologue also carries an isoleucine in this position.
The exchange is classified as ‘tolerated’ by the SIFT program
which predicts deleterious amino acid substitutions [22]. Col9A2
encodes a collagen subunit which is predominantly expressed in
cartilage [23]. The three substitutions identified in the SJL
sequence are classified as ‘tolerated’ by the SIFT program. Thus,
none of the amino acid exchanges in Smap2 and Col9a2 are likely
candidates explaining the diabetogenic effect of Nidd/SJL.
Next, we determined the expression of all 10 confirmed genes in
liver, muscle, and adipose tissue of SJL, NZO, and B6 by
quantitative PCR (data for adipose tissue shown in Figure S3).
mRNA of Col9a2 and Tmco2 was undetectable in these tissues.
With the exception of Zfp69, none of the other investigated genes
exhibited significant and consistent differences in their expression.
As is illustrated in Figure 4, mRNA levels of Zfp69 differed
markedly between the strains NZO, B6, and SJL: mRNA levels of
Zfp69 were nearly undetectable in NZO and B6, but were present
in SJL (Figure 4A). Analysis of tissues from congenic B6.SJL-Nidd/
SJL mice indicated that the expression of Zfp69 was dependent on
the genotype (B6 or SJL) of the critical interval of Nidd/SJL
(Figure 4B). These data suggested that an allelic variation of Zfp69
itself had caused its differential expression.
Identification of a loss-of-function variant of Zfp69
In order to test the possibility that the marked difference in the
RT-PCR signal (primer pair 1 in Figure 5A) between NZO and
SJL was due to the formation of different mRNA species, we
analysed the Zfp69 cDNA by RACE-PCR. Products of 59-RACE
corresponded with the reference sequence (Accession number
ENSMUST00000106280) and were identical in the two strains.
By 39-RACE, however, we detected a shorter cDNA in B6 and
NZO that contained only the first three exons fused to a short
segment of intron 3 (Figure 5B; alternative exon 3A in Figure 5A);
this segment comprised a stop codon and a polyadenylation site.
PCR with a primer matching exon 3A indicated that the shorter
cDNA was expressed in B6 but not in SJL (Figure 5C). Conversely,
the full length cDNA of Zfp69 comprising exon 4 was nearly
undetectable in B6 (Figure 5D), consistent with the results of the
Author Summary
Type 2 diabetes in humans as well as in obese mice is
caused by a combination of adipogenic and diabetogenic
gene variants. We have identified a gene that appears to be
involved in the pathogenesis of hyperglycaemia in obese
mice: in some mouse strains, the gene Zfp69 is disrupted by
a retroviral transposon (IAPLTR1a), which generates a
truncated mRNA. Disruption of the gene was associated
with a reduced susceptibility for diabetes, whereas the
normal allele enhanced hyperglycaemia in obese mice.
Zfp69 encodes a transcription factor which appears to
interfere with lipid storage in adipose tissue, and thereby
enhances lipid deposition in liver. In humans with type 2
diabetes, mRNA levels of the human orthologue of Zfp69
(ZNF642) were increased in adipose tissue. Thus, the
transcription factor ZFP69/ZNF642 may be involved in the
pathogenesis of obesity-associated diabetes.
Zfp69/ZNF642 and Obesity-Associated Diabetes
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intron 3 by PCR (Figure 5E) and sequencing indicated that B6 and
NZO carry an inserted retrotransposon (IAPLTR1a) which
functions as a gene trap by causing intronic polyadenylation and
alternative splicing. Accordingly, no immunoreactive ZFP69
protein was detected in B6 and NZO with antiserum against a
C-terminal peptide (Figure 5G). The retrotransposon was also
detected in NZL and BKS which are strains related with NZO and
B6, respectively. In contrast, SJL, NZB, NON (Figure 5F), and 5
other strains we tested (Table S3) lacked the 7115 bp insertion.
Zfp69 is a member of the subfamily of zinc finger transcription
factors that comprise a N-terminal KRAB and a zinc finger
binding C2H2 domain (Figure 5H, [24,25]. The shorter mRNA
generated in B6 and NZO encodes a truncated protein which can
be considered a loss-of-function variant since it lacks both the
KRAB and the (DNA binding) C2H2 domain of the transcription
factor.
Allelic variation of Zfp69 in mouse strains NZO, B6, NZB,
SJL, and NON corresponds with expression of Zfp69 and
with the diabetogenic effect of chromosome 4 in three
outcross populations
Several outcross experiments generating obese mouse popula-
tions have previously been performed that showed the presence
(NZOxNON, [10]; NZOxSJL, [11]; NZOxNZB, Schmolz et al.,
unpublished) or absence (NZOxB6, Vogel et al., unpublished) of a
diabetogenic allele in the vicinity of D4Mit278 on chromosome 4.
According to these data, NON and SJL contributed a major
diabetogenic effect (Nidd1 and Nidd/SJL). In addition, distal
chromosome 4 of NZB (D4Mit203) contributed to the hypergly-
caemia of the (NZOxNZB)F2 (blood glucose in wk 22: genotype
NZO/NZO, 301632; NZO/NZB, 389619; NZB/NZB,
376628 mg/dl; p,0.05 for differences to NZO/NZO). Based
on these data, we expected that SJL, NON, and NZB carry an
identical (diabetogenic) allele of Zfp69, and that NZO and B6 both
Figure 1. Location and diabetogenic effect of QTL Nidd/SJL on distal mouse chromosome 4. (A) LOD score curve of Nidd/SJL derived from
a (NZOxSJL)N2 backcross population of 207 male mice. The approximate position of the Nidd1 QTL harboring a diabetogenic allele from NON was
obtained from Leiter et al. [10]. (B,C) The chromosomal segment D4Mit175–D4Mit233 of SJL was introgressed into B6, and a (NZOxB6.SJL-Nidd/SJL)N2
backcross population was generated. Blood glucose (B) and weight gain (C) in male backcross mice were monitored weekly. Data represent
means6SE.
doi:10.1371/journal.pgen.1000541.g001
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different mouse strains to hyperglycaemia in the intercross
populations corresponded with the allelic variation of Zfp69 in
these strains (Figure 5F). These data are consistent with the
hypothesis that loss of function of Zfp69 supresses diabetes, and
that complementation by the ‘wild-type’ allele as in SJL enhances
obesity-associated diabetes.
Insertion of the retrotransposon IAPLTR1a produces
aberrant mRNA species of eight genes in the B6 genome
Endogenous retroviral elements such as IAP and ETn/MusD
retrotransposons have previously been shown to be significant
genomic mutagens [26], and appear to contribute substantially to
the genetic heterogeneity of mouse strains. In order to test the
possibility that IAPLTR1a insertion generates variant transcripts
of other genes in the B6 genome, we used a bioinformatic
approach and identified all insertions of the retrotransposon by an
alignment with its 338 bp LTR sequence. This alignment
identified 33 integrations into introns of genes. Subsequently, all
EST clones that mapped to the position of these genes were
identified and aligned with the reference cDNAs. With this
procedure, a total of 8 genes including the previously reported
Adamts13 [27] were found (Table 1) that generated aberrant
mRNA species (premature polyadenylation or alternative tran-
scription start) due to the insertion of the IAPLTR1a.
Characterization of B6-ob/ob mice carrying the
diabetogenic Zfp69 allele
In order to study the functional consequences of the presence or
absence of Zfp69 mRNA as seen in B6 vs. SJL, we combined the ob
mutation with Nidd/SJL on the B6 background. Obese mice
homozygous for the SJL allele of Zfp69 exhibited the same time
course of weight gain as carriers of the B6 allele (loss-of-function
variant; Figure S4A), but significantly higher blood glucose
Figure2. Identificationof a critical interval of mouse chromosome 4 harboringthediabetogenicallele Nidd/SJL. (A)Mapof chromosomal
segments I-IV of SJL introgressed into the B6 background. (B) Blood glucose (wk 12) and weight gain (wk 12–17) of male mice from a (NZOxB6.SJL-Nidd/
SJL)N2 male backcross mice generated with the recombinant congenic lines. Data represent means6SE of a number of mice given in parenthesis.
doi:10.1371/journal.pgen.1000541.g002
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(Figure 6B). Most strikingly, the SJL genotype of 13 weeks old
B6-ob/ob.SJL-Nidd/SJL mice was associated with a significant
increase (30%) in liver triglyceride content (Figure 6C) and weight
(data not shown), and with a pronounced reduction (60%) of
gonadal (epididymal) fat (Figure 6D). The reduction in gonadal fat
mass appeared to precede the hepatosteatosis of B6-ob/ob.SJL-
Nidd/SJL mice, since in younger animals (8 weeks), a difference
between genotypes in gonadal fat, but not in hepatic weight which
paralleles hepatosteatosis was observed (Figure S5). Thus, Nidd/
SJL might have caused a moderate lipid storage defect, and a
redistribution of triglycerides to ectopic stores.
Interaction of the diabetogenic alleles Nidd/SJL (Zfp69
SJL)
and Nob1 (Tbc1d1
NZO)
We have previously reported that the diabetogenic effect of Nidd/
SJL was accelerated and aggravated by a QTL on chromosome 5
(Nob1) [12]. More recently, we have identified the RabGAP Tbc1d1
as the gene responsible for the effect of Nob1 [16]. Tbc1d1
NZO
reduced fatty acid oxidation in muscle, thereby enhancing obesity
and diabetes susceptibility. Increased levels of ectopic triglycerides
causedbyZfp69 would thereforeexplain the interaction ofNidd/SJL
with Nob1. In order to strengthen this point, we analysed the data of
the NZOxSJL intercross for an earlier time point (Figure S6). This
analysis indicated that the diabetogenic Zfp69
SJL allele required
Figure 3. Map of the critical interval of Nidd/SJL. (A) The interval was determined by introgression of segments III and IV (Figure 2) of SJL into
B6, and was initially defined by the markers D4Mit76, D4Mit123, and D4Mit12. Further fine-mapping with SNPs (Figure S2) restricted the interval to a
region between the genes Nfyc and Ppt1 (red segment). (B) Comparison of the segment with the human syntenic region on chromosome 1.
doi:10.1371/journal.pgen.1000541.g003
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NZO in order to significantly increase blood glucose and
plasma insulin levels in week 10.
Increased mRNA levels of ZNF642, the human orthologue
of Zfp69, in white adipose tissue of patients with type 2
diabetes
In order to test the possibility that the human orthologue of
Zfp69 is involved in the pathogenesis of human type 2 diabetes, we
determined its expression in omental and subcutaneous white
adipose tissue of diabetic and control individuals. As is illustrated
in Figure 7, mRNA levels of ZNF642 were significantly higher in
diabetic patients than in controls in both omental and subcuta-
neous adipose tissue. In addition, there was a significant
correlation of HbA1c levels with ZNF642 mRNA (r=0.32;
p,0.006). Subgroup analysis indicated that the correlation was
significant in overweight (BMI.25; r=0.34; p=0.002) but not in
lean (BMI,25; r=20.09; p=0.74) individuals.
Discussion
The present data identify the zinc finger domain transcription
factor Zfp69 as the most likely candidate for the diabetogenic effect
of the mouse QTL Nidd1 and Nidd/SJL which aggravates and
accelerates obesity-associated diabetes in the NZO strain, and
enhances hyperglycaemia in B6-ob/ob mice. The following
arguments can be made in favour of this conclusion:
1. With interval-specific congenics, we defined a critical genomic
interval with 10 genes that was required to enhance diabetes in
NZO mice,
2. of the 10 genes located in that interval, Zfp69 exhibited the
most pronounced allelic variation in that the gene was
‘trapped’ by a retrotransposon,
3. this allelic variation corresponded with the diabetogenic or
diabetes-resistant effect of the QTL in five mouse strains, and
Figure 4. Expression of Zfp69 is suppressed in NZO and B6. (A) mRNA levels of Zfp69 in liver, skeletal muscle, and epididymal adipose tissue
from parental SJL, B6, and NZO strains as determined by quantitative RT-PCR. (B) Differential expression of Zfp69 mRNA is dependent on the
genotype of the Zfp69 locus (D4Mit123). For this analysis, congenic B6.SJL-Nidd/SJL homozygous for the ob-mutation were used. Asterisks indicate
significance of difference to B6/NZO (p,0.001).
doi:10.1371/journal.pgen.1000541.g004
Zfp69/ZNF642 and Obesity-Associated Diabetes
PLoS Genetics | www.plosgenetics.org 6 July 2009 | Volume 5 | Issue 7 | e10005414. expression of the human orthologue of Zfp69 is increased in
adipose tissue of human diabetics, supporting the hypothesis
that the gene is involved in adipose tissue function.
Surprisingly, diabetes appears to be produced by ‘rescue’ of a
loss-of-function variant of Zfp69: NZO mice and the diabetes-
resistant B6 strain express a truncated mRNA, whereas the
diabetogenic allele from SJL and NON produces a ‘normal’
expression of Zfp69.
Identification of Zfp69 as the causal gene crucially depends on
exclusion of other variations in the critical region. Firstly, Zfp69
was the only gene in the region exhibiting a significant differential
expression in liver, adipose tissue, muscle or pancreas. Secondly,
the T257I substitution in SMAP2 is outside of the functional
Figure 5. Loss-of-function of Zfp69 in NZO and B6 by alternative mRNA splicing and intronic polyadenylation. (A) Genomic
organisation and PCR primer pairs used for characterization of Zfp69. (B) Sequence of the additional exon 3A (capital letters) that was polyadenylated
and spliced to exon 3 as identified by 39-RACE–PCR. (C,D) Identification of the cDNA variants in B6 and SJL by PCR with downstream primers derived
from exons 3A and 4. (E) Detection of the 7 kbp insertion in intron 3 of B6. (F) allelic variation of Zfp69 in different mouse strains with known
contribution of distal chromosome 4 to diabesity. (G) Western blot of nuclear extracts isolated liver of NZO, B6, and SJL mice. Co, recombinant ZFP69
generated by transfection of COS-7 cells with Zfp69 cDNA. (H) Model of the domain structure of ZFP69 and the truncated variant (B6, NZO).
doi:10.1371/journal.pgen.1000541.g005
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corresponds with the human sequence, and is classified as
‘tolerated’ by a method predicting deleterious substitutions [22].
Thirdly, the three non-synonymous exchanges in Col9a2 were also
classified as ‘tolerated’. Furthermore, we failed to detect mRNA of
Col9a2 in insulin-sensitive tissues or pancreas by PCR. The gene
encodes a subunit of the extracellular matrix protein collagen type
IX which is involved in cartilage and bone function [23]. Loss-of-
function mutations cause multiple epiphyseal dysplasia in humans,
and skeletal abnormalities in mice [28,29]. Thus, none of the other
nine genes in the critical region are likely candidates for the
diabetogenic effect of Nidd/SJL.
In order to further elucidate the diabetogenic effect of Nidd/SJL,
and to link it with a cellular function of Zfp69
SJL, we have studied
B6.SJL-Nidd/SJL mice rendered obese by the ob mutation (B6.V-
Lep
ob X B6.SJL-Nidd/SJL). Because of their monogenic obesity,
these mice are much more homogeneous than the polygenic
(NZOxSJL)F2 intercross population. The effects observed in these
mice are consistent with the hypothesis that Nidd/SJL produced a
redistribution of triglycerides from gonadal adipose tissue to
ectopic stores such as liver, thereby causing hyperglycaemia
through an aggravated insulin resistance. With such a scenario, we
hypothesize that Zfp69
SJL primarily causes a reduced storage
capacity of epididymal adipose tissue. Zfp69
SJL belongs to a family
of transcription factors that comprise the conserved Kru ¨ppel-
associated box (KRAB) in addition to the zinc finger DNA binding
domain [25]. The KRAB domain appears to activate co-
repressors, resulting in a suppression of target genes [30]. By
analogy, we speculate that the normal Zfp69 allele suppresses
genes required for expansion of adipose tissue stores. It should be
noted, however, that this hypothesis requires definitive proof by a
direct identification of the genes regulated by Zfp69.
Interestingly, the above described scenario would explain the
previously observed interaction between the diabetogenic Nidd/SJL
allele and Nob1/Tbc1d1 [12]. We have recently shown that the
normal Tbc1d1 allele reduces fatty acid oxidation in muscle, thereby
enhancing obesity and diabetes susceptibility [16]. Redistribution of
triglycerides caused by Zfp69 would enhance the deleterious effects
of the reduced fat oxidation, and explain the accelerated onset of
diabetes observed in the presence of both diabetogenic alleles [12].
However, we cannot fully rule out additional effects of Zfp69 on
other tissues such as muscle or pancreas.
ItshouldbenotedthatthediabetogeniceffectoftheZfp69variant
is markedly dependent on interaction with other genes contributed
by the background strain. Zfp69 requires obesity in order to produce
hyperglycaemia (‘diabesity’), and needs other diabetogenic alleles in
order to produce beta cell failure, hypoinsulinaemia, and weight
loss. So far, we could not detect beta cell destruction on the B6
background. On the NZO background, it was the interaction with
NZO alleles on chromosomes 1 and 15 that enhanced the
diabetogenic effect of Zfp69 [Vogel et al., unpublished].
The production of an aberrant mRNA by alternative splicing is
common in human inherited disease. Here, we have identified an
unusual mechanism: a truncated Zfp69 mRNA was generated by
insertion of a retrotransposon comprising a polyadenylation signal
and a splicing acceptor site into intron 3. By a similar mechanism,
expression of the endothelin B receptor is reduced in piebald mice
[31]. Furthermore,it was shown recently that humansoluble VEGF
receptor is generated, and its abundance regulated, by intronic
polyadenylation and alternative splicing [32]. In addition, an IAP
retrotransposon causes intronic polyadenylation of the mouse
Adamts13 gene [27]. Our in-silico search identified at least 7
additional genes with insertions of the IAPLTR1a that produced
aberrant transcripts by the same mechanism of intronic polyade-
nylation and alternative splicing. Together with our functional data
on the trapping of Zfp69 by IAPLTR1a, this finding supports the
previous suggestion [26] that insertion of retroviral elements is an
important contributor to the genetic heterogeneity of mouse strains.
Materials and Methods
Animals
NZO mice from our own colony (NZO/HIBomDife: Dr. R.
Kluge, German Institute of Human Nutrition, Nuthetal, Germany),
Table 1. Gene variants in B6 mice caused by integration of
the IAPLTR1a_Mm sequence.
Gene Position Aberrant EST/mRNA Modification
Fmo1 1qH2.1 AI132203 truncated mRNA
AK042457
BB242793
BF121776
Adamts13 2qA3 AB071302 truncated mRNA
EU034706
Cdk5rap1 2qH1 AW908483 alternative
transcription start
BB842254
DV051174
W82224
W82241
Sgip1 4qC6 AK049616 truncated mRNA
Zfp69 4qD2.2 BB795296 truncated mRNA
CJ244124
CJ244263
CJ244311
Grid2 6qC1 BY035709 truncated mRNA
BY036240
Cpne8 15qE3 AI853527 truncated mRNA
AK005311
AW548480
BC048551
BC076564
BQ553434
BQ553435
BU846828
BY705490
CA451877
DV040130
DV054241
Lrrc33 16qB2 BY035709 alternative
transcription start
BY036240
BLAT search with 338 bp of the IAPLTR1a_Mm sequence identified 202
integrations into the B6 genome (90 retrotransposons flanked with LTR
sequences and 22 isolated LTR sequences). Thirty-three of the integrations were
located in introns of genes. In 8 transcripts modifications caused by the LTR
motive were identified; 6 led to a truncated mRNA, and 2 generated an
alternative transcription start. Variants in the Adamts13 mRNA caused by the
IAPLTR1a_Mm sequence were previously described [27].
doi:10.1371/journal.pgen.1000541.t001
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6JCrl, Charles River, Sulzfeld, Germany) were used throughout.
Mice were housed at a temperature of 22uC with a 12:12 hours light-
dark cycle (lights on at 6:00 a.m.) in type II or type III macrolon cages
with soft wood bedding. Standard chow (maintenance diet for rats
andmice,No. V153xR/M-H,Ssniff,Soest,Germany)contained(w/
w) 19% protein, 3.3% fat, and 54.1% carbohydrates, with 23%, 8%,
and 69% of total digestible energy (11.8 kJ/g) from protein, fat, and
carbohydrates, respectively. The high-fat diet (No. C1057, Altromin,
Lage, Germany) contained (w/w) 17% protein, 15% fat, and 47%
carbohydrates, with 17%, 35%, and 48% of total digestible energy
(16.2 kJ/g) from protein, fat, and carbohydrates. The animals were
kept in accordance with the NIH guidelines for care and use of
laboratory animals, and all experiments were approved by the Ethics
Committee of the Ministry of Agriculture, Nutrition and Forestry of
the State of Brandenburg, Germany.
Breeding strategy
SJL mice were backcrossed three times to B6. The progeny was
genotyped with microsatellite markers and selected for the
Figure 6. Effect of the Zfp69
SJL allele in B6.V-Lep
ob mice. Nidd/SJL was combined with a B6.V-Lep
ob background by intercross, and male B6-ob/
ob.SJL-Nidd/SJL (SJL/SJL) were compared with obese control mice (B6/B6). Postabsorptive (6 h fasting) blood glucose levels (A), liver triglyceride
content (C), and weight of gonadal fat pads (D) were determined at week 13, plasma triglycerides (B) at week 28. Data represent means6SE of 10
(A,C,D) or 24 mice (B).
doi:10.1371/journal.pgen.1000541.g006
Figure 7. Expression of ZNF642 in adipose tissue of human
individuals with (T2D) and without (no) type 2 diabetes. mRNA
levels were determined by qRT–PCR in subcutaneous (sc) and visceral
adipose tissue from 67 controls and 31 individuals with type 2 diabetes.
doi:10.1371/journal.pgen.1000541.g007
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B6.SJL-Nidd/SJL mice were mated with NZO. The resulting F1
generation was backcrossed to NZO (N2) or intercrossed (F2). B6-
ob/ob.SJL-Nidd/SJL mice were generated by mating B6.SJL-Nidd/
SJL animals (defined by markers D4Mit175 and D4Mit251) with
B6.V-Lep
ob mice heterozygous for the ob allele. Residual SJL donor
DNA from other chromosomes as determined by genome-wide
SNP genotyping (KBioscience, UK) was 2.9% in the
(NZOxB6.SJL-Nidd/SJL)N2 progeny (Figure 2), and 7.7% in B6-
ob/ob.SJL-Nidd/SJL mice (Figure 6, Figure S4, S5, S6). For linkage
analysis and phenotypic characterization, male mice were used
throughout.
Analysis of body composition
Body fat and lean mass were determined with a nuclear
magnetic resonance spectrometer (Bruker Minispec instrument,
Echo Medical Systems, Houston, TX, USA). Conscious mice were
placed in an applied static field for 0.9 minutes [33]. In addition,
body weights were measured with an electronic scale.
Serum parameters
Blood samples were collected at 8:00–9:00 a.m. from mice that
had free access to food and water unless indicated otherwise.
Glucose levels were determined with a glucometer elite (Bayer
HealthCare, Leverkusen, Germany). Triglyceride levels were
measured with Triglyceride Reagent (Sigma, Steinheim, Ger-
many) according to manufacturers’ instructions. Values were
corrected for free glycerol using Free Glycerol Reagent (Sigma).
Hepatic triglycerides
Hepatic triglyceride content was determined by an enzymatic
assay (Randox, Crumlin, United Kingdom) after chloroform/
methanol extraction according to manufacturers’ instructions.
Genotyping
DNA was prepared from mouse tails with a DNA isolation kit
based on a salt precipitation method (InViTek, Berlin, Germany).
Animals were genotyped for polymorphic microsatellite markers
(Table S1) by PCR with oligonucleotide primers obtained from
MWG (Ebersberg, Germany), and microsatellite length was
determined by non-denaturing polyacrylamide gel electrophoresis.
Genotyping of SNPs was performed by sequencing.
Sequencing
Sequencing of DNA was performed with a 3130xl Genetic
Analyzer (Applied Biosystems, Darmstadt, Germany) using the
BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosys-
tems). Sequence analysis was done by SeqScape software 2.5
(Applied Biosystems).
Quantitative real-time PCR
Total RNA from epididymal mouse white adipose tissue was
isolated with the RNeasy Lipid Tissue Mini Kit (QIAGEN,
Hilden, Germany) according to manufacturers’ instructions. Total
RNA from liver and skeletal muscle was extracted with peqGOLD
RNA Pure reagent (PeqLab Biotechnologie GmbH, Erlangen,
Germany). First strand cDNA synthesis was prepared with 2.0 mg
total RNA, random hexamer primer, and SuperscriptIII reverse
transcriptase (Invitrogen, Carlsbad, CA). Quantitative real-time
PCR was performed with an Applied Biosystems 7300 Real-time
PCR system, with TaqMan Gene Expression Master Mix (Applied
Biosystems), 25 ng cDNA, and TaqMan Gene Expression Assays
(Applied Biosystems, Table S2).
RACE PCR
Rapid amplification of cDNA ends was performed with the
FirstChoice RLM-RACE Kit (Ambion, Darmstadt, Germany)
according to manufacturers’ instructions.
Nuclear extract preparation and western blot analysis
Nuclear extracts were prepared from livers of NZO, SJL, and
C57BL/6 mice as described previously [34] and analyzed by
western blotting [35] with an affinity purified polyclonal antibody
raised against a Zfp69-specific peptide (KRQEGNKLENPESS).
Analysis of human ZNF642 mRNA expression in
subcutaneous and visceral adipose tissue
Paired samples of subcutaneous and visceral adipose tissue were
obtained from 98 Caucasian men and women, 31 individuals with
type 2 diabetes and 67 with normal glucose tolerance test, who
underwent open abdominal surgery for weight reduction surgery,
cholecystectomy, abdominal injuries, or explorative laparotomy.
19 individuals were lean as defined by a BMI,25 kg/m
2 and 79
subjects were overweight or obese (BMI.25 kg/m
2). Samples
were immediately frozen in liquid nitrogen after sampling. All
subjects gave written informed consent before taking part in the
study which was approved by the ethics committee of the
University of Leipzig.
Total RNA was isolated from adipose tissue samples with
TRIzol (Life Technologies, Grand Island, NY), and 1 mg RNA
was reverse transcribed with standard reagents (Life Technolo-
gies). Human ZNF642 gene expression was measured by
quantitative real-time RT-PCR in a fluorescent temperature
cycler by TaqMan assay. From each RT-PCR, 2 ml cDNA as well
as 1 ml of primer/probe mixture (MWG) was amplified in a 20 ml
PCR with the Universal Master Mix Reagent from Applied
Biosystems according to the manufacturers’ instructions. Samples
were incubated in an ABI PRISM 7000 sequence detector
(Applied Biosystems) for an initial denaturation at 95uC for
10 min, followed by 40 PCR cycles, each cycle consisting of 95uC
for 15 s, 60uC for 1 min, and 72uC for 1 min. The following
primers were used: human ZNF642; left primer: CAT GGA TGG
CAG AGA AAG AAG; right primer: GCT CCT GTG AAA
TGG TAC TC; dual-labeled probe: CCA GGA GAT CCC AGT
TCA GAC TTG A. The 18sRNA served as endogenous control
and was determined by a premixed assay on demand for human
18S rRNA (ABI). Human ZNF642 mRNA expression was
calculated using the Delta CT method [36].
Statistical analysis
Means of body weights, blood glucose, and insulin levels of the
backcross (Figure 2) and intercross progeny (Figure S1, Figure S6)
were compared by ANOVA (post-hoc tests: Dunnett’s or Games-
Howell test, depending on the homogeneity of variances) after
testing for homogeneity of variances by Levene’s test. Blood
glucose values were log-transformed before the analysis. Differ-
ences between B6/B6 and SJL/SJL genotypes (Figure 6, Figure
S5) were tested by two-tailed Student’s t-test. Expression levels
determined by quantitative real-time PCR were compared by the
nonparametric Kruskal-Wallis H-test (Figure 4, Figure S3).
Supporting Information
Figure S1 Diabetic hyperglycaemia and diabetes-associated
growth retardation in male (NZOxB6.SJL-Nidd/SJL)F2 mice
carrying the SJL allele of Nidd/SJL on the NZO background.
After weaning, mice were kept on a high-fat diet (15% (w/w) fat,
47% carbohydrates, 17% protein), and blood glucose and body
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Nidd/SJL locus or the corresponding NZO allele were included in
the experiment. (A) Time course of non-fasted blood glucose. Data
represent means6SE of 34, 70, and 110 homozygous (for SJL
allele), heterozygous, and control mice, respectively. (B) Time
course of body weight gain. Means6SE of the same number of
animals as in A.
Found at: doi:10.1371/journal.pgen.1000541.s001 (0.19 MB TIF)
Figure S2 Localisation of SNPs and microsatellite markers used
for fine mapping of the critical interval as defined by the backcross
animals N2-III and N2-IV carrying the segments III and IV.
Yellow colour depicts heterozygosity for the SJL allele. The critical
interval is highlighted by the red frame.
Found at: doi:10.1371/journal.pgen.1000541.s002 (0.44 MB TIF)
Figure S3 Relative expression of genes located in the critical
interval of Nidd/SJL. mRNA levels in epididymal adipose tissue
were determined by quantitative RT-PCR, and data were
normalized for values obtained from B6. mRNA of Col9a2 and
Tmco2 was not detectable after 35 PCR cycles. Data are
means6SD of 5 mice in each group.
Found at: doi:10.1371/journal.pgen.1000541.s003 (0.12 MB TIF)
Figure S4 Weight gain and postabsorptive blood glucose in
B6.V-Lep
ob mice with or without the Zfp69
SJL allele. After weaning,
male homozygous B6-ob/ob.SJL-Nidd/SJL (SJL/SJL) mice and
obese controls (B6/B6) were kept on a high-fat diet, and body
weight (A) and 6 h fasting blood glucose (B) was monitored weekly.
(A) Data represent means6SE of 26, 36, and 21 homozygous
(SJL/SJL), heterozygous, and control mice (B6/B6), respectively.
(B) Data represent means6SE of 14 homozygous (SJL/SJL) and
15 control mice (B6/B6).
Found at: doi:10.1371/journal.pgen.1000541.s004 (0.18 MB TIF)
Figure S5 Fat depots and liver triglycerides in B6.V-Lep
ob mice
with or without the Zfp69
SJL allele. Liver weights and weights of
gonadal (epididymal), subcutaneous, and mesenteric adipose tissue
were determined in 8 weeks old homozygous B6-ob/ob.SJL-Nidd/
SJL (SJL/SJL) and obese control mice (B6/B6). Data represent
means6SE of 6 (SJL/SJL) and 8 (B6/B6) mice.
Found at: doi:10.1371/journal.pgen.1000541.s005 (0.12 MB TIF)
Figure S6 Interaction of the variant Zfp69 and Tbc1d1 alleles in
a backcross of NZO with SJL. Blood glucose (A) and immuno-
reactive insulin (B) was determined in 10 weeks old male
(NZOxSJL)N2 progeny (N=207) that were stratified according
to the indicated genotype. The SJL allele of Tbc1d1 represents a
loss-of-function variant and enhances fatty acid oxidation in
muscle (16); the SJL allele of Zfp69 reduces fat storage in gonadal
adipose tissue (Figure 6C).
Found at: doi:10.1371/journal.pgen.1000541.s006 (0.20 MB TIF)
Table S1 Microsatellite markers for genotyping of the Nidd/SJL
locus.
Found at: doi:10.1371/journal.pgen.1000541.s007 (0.04 MB
DOC)
Table S2 TaqMan Gene Expression Assays (Applied Biosys-
tems).
Found at: doi:10.1371/journal.pgen.1000541.s008 (0.04 MB
DOC)
Table S3 Presence (+) or absence (2) of the IAPLTR1a
retrotransposon in the Zfp69 gene of different mouse strains.
Found at: doi:10.1371/journal.pgen.1000541.s009 (0.04 MB
DOC)
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